Table A1.
ACCENT Trials Used for Early Mortality Analyses
| Trial | Years | Treatment Arm | No. of Participants |
|---|---|---|---|
| NSABP C01 | 1977-1983 | Surgery alone v MOF | 724 |
| NSABP C02 | 1984-1988 | Surgery alone v PVI + 5-FU | 686 |
| NSABP C03 | 1987-1989 | MOF v FU + LV | 1,042 |
| NSABP C04 | 1989-1990 | 5-FU + LEV v 5-FU + LV v 5-FU + LV + LEV | 2,083 |
| NSABP C05 | 1991-1994 | 5-FU + LV v 5-FU + LV + IFN | 2,136 |
| NSABP C06 | 1997-1999 | IFU + LV v UFT + LV | 1,556 |
| NSABP C07 | 2000-2002 | 5-FU + LV v FOLFOX | 2,434 |
| NSABP C08 | 2004-2006 | mFOLFOX6 ± Bev | 2,612 |
| CALGB 89803 | 1999-2001 | 5-FU + LV v 5-FU + LV + IFL | 1,239 |
| FFCD | 1982-1990 | Surgery alone v 5-FU + LV | 256 |
| GERCOR | 1996-1999 | Bolus v infusional 5-FU + LV | 900 |
| GIVIO | 1989-1992 | Surgery alone v 5-FU + LV | 846 |
| INT-0035 | 1984-1987 | Surgery alone v 5-FU + LEV | 926 |
| INT-0089 | 1990-1992 | 5-FU + LEV v 5-FU + LV (HD or LD) v 5-FU + LV + LEV | 3,363 |
| MOSAIC | 1998-2001 | 5-FU + LV v FOLFOX | 2,241 |
| NCCTG-78-48-52 | 1978-1984 | Surgery alone v 5-FU + LEV | 247 |
| NCCTG-87-46-51 | 1988-1989 | Surgery alone v 5-FU + LV | 408 |
| NCCTG-89-46-51 | 1989-1991 | 5-FU + LV ± LEV for 6 or 12 months | 914 |
| NCCTG-91-46-53 | 1993-1998 | 5-FU + LV + HD or standard LEV | 878 |
| NCIC | 1987-1992 | Surgery alone v 5-FU + LV | 359 |
| PETACC-3 | 1999-2002 | 5-FU + LV (AIO or LVFU2) v ± IFL | 3,186 |
| QUASAR | 1994-1997 | 5-FU + LV (HD or LD) ± LEV | 3,507 |
| SWOG 9415 | 1995-1999 | Bolus v infusional 5-FU + LEV + LV | 939 |
| SIENA | 1984-1990 | Surgery alone v 5-FU + LV | 239 |
| XACT | 1998-2001 | 5-FU + LV v Cap | 1,983 |
| XELOXA | 2003-2004 | 5-FU + LV v XELOX | 1,864 |
| Complete ACCENT database | 1977-2004 | 37,568 |
Abbreviations: 5-FU, fluorouracil; AIO, folic acid, fluorouracil, and irinotecan; Bev, bevacizumab; CALGB, Cancer and Leukemia Group B; Cap, capecitabine; FOLFOX, fluorouracil, leucovorin, and oxaliplatin; GERCOR, Groupe d’Etude et de Recherche Clinique en Oncologie et Radiothérapie; HD, high dose; IFL, irinotecan; IFN, interferon alfa-2a; INT, Intergroup; LD, low dose; LEV, levamisole; LV, leucovorin; LVFU2, semimonthly fluorouracil and leucovorin; mFOLFOX6, modified FOLFOX; MOF, semustine, vincristine, and fluorouracil; NCCTG, North Central Cancer Treatment Group; NSABP, National Surgical Adjuvant Breast and Bowel Project; PVI, portal vein infusion; SWOG, Southwest Oncology Group; UFT, tegafur-uracil; XELOX, intravenous oxaliplatin plus oral capecitabine.